BMY addendum—Breyanzi is the first CAR-T to show efficacy in CLL, as far as I know. rrCLL is a large market; if Breyanzi’s complete-response rate after, say, 5 years is as high as 15-20%, this indication could be a meaningful commercial contributor.
Breyanzi, which is currently approved for various forms of relapsed NHL, has annualized sales of under $200M.
Market Data 
Markets 
AI
